Bebetter Med
BeBetter Med is a Guangzhou-based biopharmaceutical company (SSE STAR: 688759) developing first-in-class small molecule and dual siRNA therapeutics across oncology, cardiometabolic, CNS, and kidney diseases, with one approved product (Ifupinostat for r/r DLBCL) and a 14+ candidate pipeline spanning four proprietary technology platforms.
- Company typePublic
- Founded2012
- HeadquartersGuangzhou, China
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Bebetter Med does
BeBetter Med (Guangzhou BeBetter Medical Pharmaceutical Co., Ltd.) is a China-headquartered clinical-stage biopharmaceutical company founded in 2012 that designs first-in-class therapeutics across oncology, cardiometabolic disease, CNS, and kidney indications. Its portfolio is organized around four proprietary technology platforms: a Targeted Small Molecule platform that uses dual pharmacophore chemistry to build dual-target inhibitors; a GDOC platform for liver-targeted dual siRNA; a POC-Nervous System platform for CNS and peripheral nervous system delivery via peptide-oligonucleotide conjugates; and a POC-Kidney platform for renal tubular epithelial cell targeting. The most advanced commercial asset is Ifupinostat (BEBT-908), a globally first-in-class HDAC/PI3Kα dual-target inhibitor that received NMPA approval on July 2, 2025 for relapsed/refractory diffuse large B-cell lymphoma and has subsequently been included in the CSCO and Chinese national lymphoma guidelines (2026 edition). The pipeline additionally includes BEBT-209 (highly selective CDK4 inhibitor in seamless Phase IIb/III for mTNBC), BEBT-109 (EGFR exon 20 selective inhibitor in NSCLC), BEBT-701 (AGT/PCSK9 dual siRNA with both NMPA and FDA clearance), BEBT-503 (pan-PPAR agonist for MASH), and preclinical assets spanning Parkinson's, Alzheimer's, gout, and renal anemia.
The company monetizes via two complementary streams: domestic pharmaceutical product sales through hospital and specialty pharmacy channels in China following NMPA approval, and out-licensing or regional partnership arrangements with global pharma counterparties (revenue mechanics governed by milestone payments and royalties under flexible deal structures). Pricing is determined through Chinese government reimbursement and institutional procurement rather than public list pricing. The company went public on the Shanghai Stock Exchange STAR Market on October 28, 2025 under ticker 688759 and operates a wholly-owned US subsidiary, BeBetter Pharma Inc., in Waltham, Massachusetts to drive global clinical development and BD activity. BeBetter Med is presently organized with 51–100 employees and an active commercial team build-out in Beijing, Shanghai, and Guangzhou.
Bebetter Med firmographics
Firmographics- Name
- Bebetter Med
- Legal name
- Guangzhou BeBetter Medical Pharmaceutical Co., Ltd. (广州必贝特医药股份有限公司)
- Website
- https://bebettermed.cn
- Company type
- Public
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- BeBetter Med is a Guangzhou-based biopharmaceutical company (SSE STAR: 688759) developing first-in-class small molecule and dual siRNA therapeutics across oncology, cardiometabolic, CNS, and kidney diseases, with one approved product (Ifupinostat for r/r DLBCL) and a 14+ candidate pipeline spanning four proprietary technology platforms.
- Ownership category
- akta.pro rank
Bebetter Med industry classification
Industry- Product category
- Oncology Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)
- akta.pro secondary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
Keywords
Where Bebetter Med is headquartered
LocationHeadquarters
- HQ city
- Guangzhou
- HQ country
- China
- HQ region
- Asia
Offices2 records
Markets served
Bebetter Med business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Pharmaceutical Product Sales: Revenue from sale of approved drugs, including Ifupinostat (BEBT-908, marketed as 贝特琳®) which received NMPA approval in July 2025 for r/r DLBCL treatment
- Licensing and Partnership Deals: Revenue from out-licensing proprietary technologies and drug candidates to global pharmaceutical partners for clinical development and commercialization
- Strategic Partnerships: Revenue potential from collaborative development arrangements including co-development, option agreements, and regional partnerships for cardiovascular metabolism, oncology, CNS, and kidney disease programs
Distribution channels2 records
Marketing channels5 records
Bebetter Med product offering
Product offeringCore offering
Bebetter Med is a biopharmaceutical company that discovers, develops, and commercializes first-in-class dual-target small molecule drugs and oligonucleotide therapeutics (dual siRNA and peptide-oligonucleotide conjugates) for oncology, cardiovascular-metabolic diseases, CNS, and kidney diseases. The company sells its approved drug Ifupinostat (BEBT-908) for relapsed/refractory DLBCL in China and pursues out-licensing/co-development partnerships for global commercialization of its pipeline assets.
Product overview
BeBetter Med is a biopharmaceutical company (SSE Stock: 688759) specializing in pioneering research and differentiated technology pathways focused on small molecule drugs and oligonucleotide conjugates. The company's portfolio consists of four integrated technology platforms: Targeted Small Molecule Drugs (for oncology and metabolic diseases), GDOC Platform (liver-targeting dual siRNA for cardiovascular metabolic conditions), POC-Nervous System Platform (CNS and peripheral delivery), and POC-Kidney Platform (renal tubular epithelial cell targeting). The pipeline includes 14+ clinical/preclinical candidates across oncology (BEBT-908/Ifupinostat, BEBT-209, BEBT-109), cardiovascular metabolic diseases (BEBT-701, BEBT-706, BEBT-720, BEBT-503, BEBT-809), and kidney/CNS diseases (BEBT-507, BEBT-758, BEBT-756, BEBT-730, BEBT-733, BEBT-738). Ifupinostat (BEBT-908) is the company's first approved drug (NMPA approved July 2025) as a global first-in-class HDAC/PI3Kα dual-target inhibitor for r/r DLBCL.
Differentiator
Problem solved
Functional benefit
Products and services
- Ifupinostat (BEBT-908 / 贝特琳®) Global first-in-class HDAC/PI3Kα dual-target small molecule inhibitor approved in China for adult patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) who have received at least two prior lines of systemic therapy. Also in clinical development in combination with CHOP for peripheral T-cell lymphoma (PTCL). Reported 3L+ ORR 54.6% and 2L+ ORR 76.2% with favorable safety.
- BEBT-209 Highly selective CDK4 inhibitor (CDK4 activity ~6x higher than CDK6) in Phase IIb/III seamless pivotal design for metastatic triple-negative breast cancer (mTNBC) and HR+/HER2- advanced breast cancer. Reported 2-3L ORR 37.5% and median PFS of 6.8 months with manageable safety in mTNBC.
- BEBT-109 Selective small molecule EGFR inhibitor targeting EGFR exon 20 insertion mutations in non-small cell lung cancer (NSCLC). Phase Ib/II data presented at ESMO Asia 2025 showed 2L+ ORR 38.5% and median PFS of 8.9 months.
- BEBT-503 Pan-PPAR agonist small molecule that completed Phase I clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and diabetes.
- BEBT-809 Potential first-in-class 20-HETE/GPR75 dual-target small molecule inhibitor in preclinical stage for obesity treatment, designed to preserve muscle mass.
- BEBT-507 Liver-targeted single siRNA therapeutic targeting TMPRSS6 in Phase I clinical development for the treatment of polycythemia vera (PV).
- BEBT-701 (GDOC Dual siRNA) Global first-in-class AGT/PCSK9 dual-target siRNA drug built on the GDOC platform in Phase I/II clinical development for the treatment of hypertension and hyperlipidemia. Received both NMPA clinical trial approval and FDA IND clearance (IND# 180170).
- BEBT-706 (GDOC Dual siRNA) Lp(a) + PCSK9 dual-target siRNA built on the GDOC platform in preclinical development for atherosclerotic cardiovascular disease (ASCVD) risk reduction.
- BEBT-720 (GDOC Dual siRNA) CIDEB + HSD17B13 dual-target siRNA built on the GDOC platform in preclinical development for MASH (metabolic dysfunction-associated steatohepatitis).
- BEBT-758 (POC-Nervous System) Peptide-oligonucleotide conjugate targeting SNCA in preclinical development for the treatment of Parkinson's disease.
- BEBT-756 (POC-Nervous System)
Quantifiable outcome
- Ifupinostat (BEBT-908) achieved 54.6% ORR in 3rd line+ and 76.2% ORR in 2nd line+ r/r DLBCL patients
- +3 more outcomes
Companies that use Bebetter Med
Customer profileSegments1 record
Ideal customer profiles2 records
Bebetter Med technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
Bebetter Med partnerships and signals
Strategic signalScale indicators5 records
Recent moves8 records
Expansion highlights6 records
Bebetter Med competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Customer concentration
Bebetter Med social profiles
Digital presenceBebetter Med financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bebetter Med leadership team
Management profileNumber of profiles
Bebetter Med subsidiaries and ownership
Company hierarchySubsidiaries1 record
Bebetter Med funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bebetter Med M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bebetter Med
What does Bebetter Med do?
Bebetter Med is a biopharmaceutical company that discovers, develops, and commercializes first-in-class dual-target small molecule drugs and oligonucleotide therapeutics (dual siRNA and peptide-oligonucleotide conjugates) for oncology, cardiovascular-metabolic diseases, CNS, and kidney diseases. The company sells its approved drug Ifupinostat (BEBT-908) for relapsed/refractory DLBCL in China and pursues out-licensing/co-development partnerships for global commercialization of its pipeline assets.
Is Bebetter Med a public or private company?
Bebetter Med is a public company. It is classified as public and is currently operating.
When was Bebetter Med founded?
Bebetter Med was founded in 2012. It employs 51 to 100 people.
Where is Bebetter Med based?
Bebetter Med is headquartered in Guangzhou, China, in the Asia region.
How does Bebetter Med make money?
Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Partnership Deals and strategic Partnerships.
Does Bebetter Med have an API?
No public API is recorded for Bebetter Med.
What industry is Bebetter Med in?
Bebetter Med's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325412 and its SIC code is 2834.